CD8A and neoplasm: Genetic DC vaccines involve engineering DCs by transfecting them with tumor DNA, RNA, or cytokine genes to express tumor‐associated antigens or immune‐enhancing molecules or to downregulate negative regulators of DC function, thereby strengthening the three signals required for CD4+ and CD8+ T‐cell activation [252, 253].